Peer-reviewedCC BYJTO clinical and research reports
Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR
- 1Department of Biostatistics and Health Data Science, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
- 2Department of Biostatistics, School of Public Health, Virginia Commonwealth University, Richmond, Virginia
- 3Division of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, Virginia
Related
- Surgical resection for indeterminate pulmonary nodules in patients with prior breast cancer: diagnostic value and biomarker reassessment
- No Overall Survival Benefit with Adding Chemotherapy to Immunotherapy in PD-L1 TPS >= 50% NSCLC: An Agent-Stratified Reassessment
- GAN-enhanced digital twins for biomarker-guided cancer immunotherapy and adoptive cell therapy: a mini review
- Heterogeneous nuclear ribonucleoproteins depict a new predictive risk model for ovarian cancer prognosis and immunotherapy
- Lactate as a predictive biomarker and therapeutic target in cardiopulmonary bypass-associated acute kidney injury
BibTeX
@article{liu2026brief,
title = {{Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR}},
author = {Jiaqian Liu and Na Bo and Patrick Nana-Sinkam and Ying Ding},
journal = {JTO clinical and research reports},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13675807},
note = {CC BY},
}
RIS
TY - JOUR
TI - Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy—A Reanalysis of OAK and POPLAR
AU - Jiaqian Liu
AU - Na Bo
AU - Patrick Nana-Sinkam
AU - Ying Ding
PY - 2026
DA - 2026/08/31
JO - JTO clinical and research reports
UR - https://europepmc.org/article/PMC/PMC13675807
SN - 2666-3643
ER -